Human p16γ, a novel transcriptional variant of p16INK4A, coexpresses with p16INK4A in cancer cells and inhibits cell-cycle progression

Oncogene

Volumn 26, Issue 49, 2007, Pages 7017-7027

  Lin, Y C ^a   Diccianni, M B ^b   Kim, Y ^b   Lin, H H ^a   Lee, C H ^a   Lin, R J ^a   Joo, S H ^c   Li, J ^c   Chuang, T J ^a   Yang, A S ^a   Kuo, H H ^a   Tsai, M D ^a,c   Yu, A L ^a,b  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Alternative splicing; Cell cycle inhibitor; INK4A

Indexed keywords

ANKYRIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 4; LUCIFERASE; PROTEIN P16; PROTEIN P16 GAMMA; PROTEIN P16INK4A; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSCRIPTION FACTOR E2F;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CIRCULAR DICHROISM; COLONY FORMATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME INHIBITION; EXON; GENE INSERTION; GENE REPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; MONONUCLEAR CELL; NEUROBLASTOMA CELL; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; STRUCTURE ANALYSIS; T LYMPHOCYTE; ALTERNATIVE RNA SPLICING; BURKITT LYMPHOMA; CLONOGENIC ASSAY; GENETICS; IMMUNOPRECIPITATION; METABOLISM; NEUROBLASTOMA; T CELL LEUKEMIA LYMPHOMA; TWO HYBRID SYSTEM; WESTERN BLOTTING;

ALTERNATIVE SPLICING; BLOTTING, WESTERN; BURKITT LYMPHOMA; CIRCULAR DICHROISM; COLONY-FORMING UNITS ASSAY; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; E2F TRANSCRIPTION FACTORS; G0 PHASE; G1 PHASE; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LUCIFERASES; NEUROBLASTOMA; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 35548998832     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210507     Document Type: Article

References (47)

1. Andrade MA, Chacon P, Merelo JJ, Moran F. (1993). Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 6: 383-390.
2. Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R et al. (2004). Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat 24: 370-380.
3. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J et al. (1997). Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57: 832-836.
4. Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ et al. (1998). Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1: 421-431.
5. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB et al. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32.
6. Chen YJ, Chang JG, Shih LS, Chen PH, Endo M, Whang-Peng J et al. (1997). Frequent detection of aberrant RNA transcripts of the CDKN2 gene in human gastric adenocarcinoma. Int J Cancer 71: 350-354.
7. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA et al. (1994). p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551.
8. Cho JW, Jeong YW, Han SW, Park JB, Jang BC, Baek WK et al. (2003). Aberrant p16INK4A RNA transcripts expressed in hepatocellular carcinoma cell lines regulate pRb phosphorylation by binding with CDK4, resulting in delayed cell cycle progression. Liver Int 23: 194-200.
9. Diccianni MB, Chau LS, Batova A, Vu TQ, Yu AL. (1996). The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Lett 104: 183-192.
10. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. (1999). Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int J Cancer 80: 145-154.
11. Diccianni MB, Yu J, Meppelink G, de Vries M, Shao L, Gebauer S et al. (2004). 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner. J Exp Ther Oncol 4: 223-237.
12. Dyson N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262.
13. ElSharawy A, Manaster C, Teuber M, Rosenstiel P, Kwiatkowski R, Huse K et al. (2006). SNPSplicer: systematic analysis of SNP-dependent splicing in genotyped cDNAs. Hum Mutat 27: 1129-1134.
14. Fu GH, Wang Y, Xi YH, Shen WW, Pan XY, Shen WZ et al. (2005). Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1). FEBS Lett 579: 2105-2110.
15. Harland M, Mistry S, Bishop DT, Bishop JA. (2001). A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10: 2679-2686.
16. Hillman RT, Green RE, Brenner SE. (2004). An unappreciated role for RNA surveillance. Genome Biol 5: R8.
17. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD et al. (1994). Germline p16 mutations in familial melanoma. Nat Genet 8: 15-21.
18. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S et al. (1994). Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358.
19. Kim WY, Sharpless NE. (2006). The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
20. Komata T, Kanzawa T, Takeuchi H, Germano IM, Schreiber M, Kondo Y et al. (2003). Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells. Br J Cancer 88: 1277-1280.
21. Krek W, Livingston DM, Shirodkar S. (1993). Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science 262: 1557-1560.
22. Li J, Byeon IJ, Ericson K, Poi MJ, O'Maille P, Selby T et al. (1999). Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. Biochemistry 38: 2930-2940.
23. Li J, Joo SH, Tsai MD. (2003). An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. Biochemistry 42: 13476-13483.
24. Li J, Mahajan A, Tsai MD. (2006). Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45: 15168-15178.
25. Li J, Poi MJ, Qin D, Selby TL, Byeon IJ, Tsai MD. (2000). Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4. Biochemistry 39: 649-657.
26. Li J, Tsai MD. (2002). Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 41: 3977-3983.
27. Lin YC, Peng JM, Wang WB. (2000). The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. Oncogene 19: 2704-2713.
28. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ et al. (1995). A novel p16INK4A transcript. Cancer Res 55: 2995-2997.
29. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al. (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
30. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP et al. (1994). Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049.
31. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J et al. (2000). Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res 6: 1219-1228.
32. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J et al. (2001). p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7: 3481-3490.
33. Ortega S, Malumbres M, Barbacid M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
34. Pace CN. (1986). Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol 131: 266-280.
35. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
36. Robertson KD, Jones PA. (1999). Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18: 3810-3820.
37. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. (1998). Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-243.
38. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK et al. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130.
39. Serrano M. (1997). The tumor suppressor protein p16INK4a. Exp Cell Res 237: 7-13.
40. Sherr CJ. (2006). Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673.
41. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D et al. (1995). Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988-2994.
42. Suh SI, Cho JW, Baek WK, Suh MH, Carson DA. (2000a). Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett 153: 175-182.
43. Suh SI, Pyun HY, Cho JW, Baek WK, Park JB, Kwon T et al. (2000b). 5-Aza-2′-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. Cancer Lett 160: 81-88.
44. Tevelev A, Byeon IJ, Selby T, Ericson K, Kim HJ, Kraynov V et al. (1996). Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Biochemistry 35: 9475-9487.
45. Xiong Y, Zhang H, Beach D. (1993). Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7: 1572-1583.
46. Yu Y, Panhuysen C, Kranzler HR, Hesselbrock V, Rounsaville B, Weiss R et al. (2006). Intronic variants in the dopa decarboxylase (DDC) gene are associated with smoking behavior in European-Americans and African-Americans. Hum Mol Genet 15: 2192-2199.
47. Zhang Y, Xiong Y, Yarbrough WG. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.